Overview

Low-dose Interleukin-2 Treatment on Idiopathic Inflammatory Myopathy

Status:
Unknown status
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
This study aims to explore the clinical and immunological efficacy of low-dose Interleukin-2 (IL-2) on idiopathic inflammatory myopathy (IIM).
Phase:
Phase 2
Details
Lead Sponsor:
Peking University People's Hospital
Treatments:
Aldesleukin
Interleukin-2